{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T21:16:06Z","timestamp":1788988566193,"version":"build-2803163510"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1097\/ogx.0b013e31828baef9","type":"journal-article","created":{"date-parts":[[2013,5,23]],"date-time":"2013-05-23T14:41:38Z","timestamp":1369320098000},"page":"467-481","source":"Crossref","is-referenced-by-count":67,"title":["Update on Raloxifene"],"prefix":"10.1097","volume":"68","author":[{"given":"Salvatore","family":"Gizzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Saccardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tito Silvio","family":"Patrelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Berretta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampiero","family":"Capobianco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania Di","family":"Gangi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Vacilotto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Bertocco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Noventa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"Ancona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donato","family":"D\u2019Antona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni Battista","family":"Nardelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20-20210212","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1056\/NEJMra022219","article-title":"Selective estrogen-receptor modulatorsmechanisms of action and application to clinical practice.","volume":"348","author":"Riggs","year":"2003","journal-title":"N Engl J Med"},{"key":"R3-20-20210212","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1056\/NEJMe068120","article-title":"Risk-benefit profiles of raloxifene for women.","volume":"355","author":"Stefanick","year":"2006","journal-title":"N Engl J Med"},{"key":"R4-20-20210212","doi-asserted-by":"crossref","first-page":"14","DOI":"10.2174\/1874325000903010014","article-title":"Raloxifene: mechanism of action, effects on bone tissue, and applicability in clinical traumatology practice.","volume":"3","author":"Rey","year":"2009","journal-title":"Open Orthop J"},{"key":"R5-20-20210212","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1535-6108(04)00059-5","article-title":"Selective estrogen receptor modulation: concept and consequences in cancer.","volume":"5","author":"Jordan","year":"2004","journal-title":"Cancer Cell"},{"key":"R6-20-20210212","first-page":"11","article-title":"Long-term safety and efficacy of raloxifene in the prevention and treatment of postmenopausal osteoporosis: an update.","volume":"1","author":"Messalli","year":"2010","journal-title":"Int J Womens Health"},{"key":"R7-20-20210212","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/S8756-3282(01)00685-8","article-title":"The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro.","volume":"30","author":"Taranta","year":"2002","journal-title":"Bone"},{"key":"R8-20-20210212","doi-asserted-by":"crossref","first-page":"6097","DOI":"10.1210\/jc.2004-0795","article-title":"Raloxifene modulates interleukin-6 and tumor necrosis factor-alpha synthesis in vivo: results from a pilot clinical study.","volume":"89","author":"Gianni","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"R9-20-20210212","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.2001.81.1.419","article-title":"Sex steroids and bone.","volume":"81","author":"Compston","year":"2001","journal-title":"Physiol Rev"},{"key":"R10-20-20210212","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1210\/jc.2002-021877","article-title":"Raloxifene concurrently stimulates osteoprotegerin and inhibitsinterleukin-6 production by human trabecular osteoblasts.","volume":"88","author":"Viereck","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"R11-20-20210212","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.maturitas.2006.05.007","article-title":"Raloxifene therapy interacts with serum osteoprotegerin in postmenopausal women.","volume":"56","author":"Messalli","year":"2007","journal-title":"Maturitas"},{"key":"R12-20-20210212","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2165\/00003495-200868140-00008","article-title":"Raloxifene: a review of its use in the prevention of invasive breast cancer.","volume":"68","author":"Moen","year":"2008","journal-title":"Drugs"},{"key":"R13-20-20210212","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1111\/j.1365-2184.2009.00664.x","article-title":"Evaluation of Ki-67 and Bcl-2 antigen expression in breast carcinomas of women treated with raloxifene.","volume":"43","author":"Lopes-Costa","year":"2010","journal-title":"Cell Prolif"},{"key":"R14-20-20210212","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ejogrb.2011.06.020","article-title":"The effect of raloxifene on telomerase expression in breast carcinoma samples from postmenopausal women.","volume":"159","author":"dos Santos","year":"2011","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"R15-20-20210212","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1111\/j.1365-2184.2009.00615.x","article-title":"Effect of raloxifene on vascular endothelial growth factor expression in breast carcinomas of postmenopausal women.","volume":"42","author":"da Silva","year":"2009","journal-title":"Cell Prolif"},{"key":"R16-20-20210212","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00280-010-1316-y","article-title":"Tamoxifen and raloxifene suppress the proliferation of estrogen receptor-negative cells through inhibition of glutamine uptake.","volume":"67","author":"Todorova","year":"2011","journal-title":"Cancer Chemother Pharmacol"},{"key":"R17-20-20210212","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ejphar.2008.06.091","article-title":"Effects of tamoxifen and raloxifene on normal human endometrial cells in an organotypic in vitro model.","volume":"592","author":"Blauer","year":"2008","journal-title":"Eur J Pharmacol"},{"key":"R18-20-20210212","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1095\/biolreprod.104.034595","article-title":"Differential effects of estrogen and raloxifene on messenger RNA and matrix metalloproteinase 2 activity in the rat uterus.","volume":"72","author":"Helvering","year":"2005","journal-title":"Biol Reprod"},{"key":"R19-20-20210212","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/molehr\/gap045","article-title":"Differential actions of estrogen and SERMs in regulation of the actin cytoskeleton of endometrial cells.","volume":"15","author":"Flamini","year":"2009","journal-title":"Mol Hum Reprod"},{"key":"R20-20-20210212","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s00795-008-0403-1","article-title":"Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells.","volume":"41","author":"Morishima","year":"2008","journal-title":"Med Mol Morphol"},{"key":"R21-20-20210212","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.fertnstert.2005.06.029","article-title":"Procoagulant state after raloxifene therapy in postmenopausal women.","volume":"84","author":"Azevedo","year":"2005","journal-title":"Fertil Steril"},{"key":"R22-20-20210212","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2006.01.001","article-title":"Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study.","volume":"119","author":"Sgarabotto","year":"2007","journal-title":"Thromb Res"},{"key":"R23-20-20210212","first-page":"803","article-title":"Differential effects of estradiol and raloxifene on collagen biosynthesis in cultured human skin fibroblasts.","volume":"12","author":"Surazynski","year":"2003","journal-title":"Int J Mol Med"},{"key":"R24-20-20210212","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/j.1365-2362.2007.01905.x","article-title":"Role of raloxifene on platelet metabolism and plasma lipids.","volume":"38","author":"Nanetti","year":"2008","journal-title":"Eur J Clin Invest"},{"key":"R25-20-20210212","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1016\/0024-3205(94)90092-2","article-title":"Inhibitory effect of high-density lipoprotein on platelet function is mediated by an increase in nitric oxide synthase activity in platelets.","volume":"55","author":"Chen","year":"1994","journal-title":"Life Sci"},{"key":"R26-20-20210212","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1093\/jnci\/djh319","article-title":"CORE Investigators. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.","volume":"96","author":"Martino","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"R27-20-20210212","doi-asserted-by":"crossref","first-page":"3444","DOI":"10.1001\/archinte.160.22.3444","article-title":"Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.","volume":"160","author":"Johnston","year":"2000","journal-title":"Arch Intern Med"},{"key":"R28-20-20210212","doi-asserted-by":"crossref","first-page":"3609","DOI":"10.1210\/jcem.87.8.8750","article-title":"Multiple Outcomes of Raloxifene Evaluation Investigators. Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial.","volume":"87","author":"Delmas","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"R29-20-20210212","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1359\/JBMR.050509","article-title":"Continuing Outcomes Relevant to Evista (CORE) Investigators. Skeletal effects of raloxifene after 8 years: results from the Continuing Outcomes Relevant to Evista (CORE) study.","volume":"20","author":"Siris","year":"2005","journal-title":"J Bone Miner Res"},{"key":"R30-20-20210212","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/01.GME.0000058772.59606.2A","article-title":"Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.","volume":"10","author":"Jolly","year":"2003","journal-title":"Menopause"},{"key":"R31-20-20210212","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Raloxifene Use for the Heart (RUTH) Trial Investigators. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women.","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"R32-20-20210212","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1001\/jama.295.23.joc60074","article-title":"National Surgical Adjuvant Breast and Bowel Project (NSABP). Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial.","volume":"295","author":"Vogel","year":"2006","journal-title":"JAMA"},{"key":"R33-20-20210212","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation.","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"R34-20-20210212","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1093\/jnci\/djn153","article-title":"Raloxifene Use for The Heart Trial Investigators. Reduced incidence of invasive breast cancer with raloxifene among women at increased coronary risk.","volume":"100","author":"Grady","year":"2008","journal-title":"J Natl Cancer Inst"},{"key":"R35-20-20210212","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.ygyno.2009.06.006","article-title":"American Society of Clinical Oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction.","volume":"115","author":"Visvanathan","year":"2009","journal-title":"Gynecol Oncol"},{"key":"R36-20-20210212","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1158\/1940-6207.CAPR-10-0076","article-title":"National Surgical Adjuvant Breast and Bowel Project. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer.","volume":"3","author":"Vogel","year":"2010","journal-title":"Cancer Prev Res (Phila)"},{"key":"R37-20-20210212","first-page":"104","article-title":"Uterine effects of 3-year raloxifene therapy in postmenopausal women younger than age 60.","volume":"95","author":"Cohen","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R38-20-20210212","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jsbmb.2008.09.002","article-title":"Effects of selective oestrogen receptor modulators on proliferation in tissue cultures of pre- and postmenopausal human endometrium.","volume":"112","author":"Punyadeera","year":"2008","journal-title":"J Steroid Biochem Mol Biol"},{"key":"R39-20-20210212","first-page":"95","article-title":"A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium.","volume":"95","author":"Goldstein","year":"2000","journal-title":"Obstet Gynecol"},{"key":"R40-20-20210212","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0378-5122(03)00280-9","article-title":"Raloxifene therapy does not affect uterine blood flow in postmenopausal women: a transvaginal Doppler study.","volume":"47","author":"de Azevedo","year":"2004","journal-title":"Maturitas"},{"key":"R41-20-20210212","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1001\/jama.279.18.1445","article-title":"Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women.","volume":"279","author":"Walsh","year":"1998","journal-title":"JAMA"},{"key":"R42-20-20210212","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1067\/mob.2001.111065","article-title":"Randomized control study of the effects of raloxifene on serum lipids and homocysteine in older women.","volume":"184","author":"de Leo","year":"2001","journal-title":"Am J Obstet Gynecol"},{"key":"R43-20-20210212","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1080\/01443610500171060","article-title":"Evidence of improved serum fatty acid profile of postmenopausal women receiving atorvastatin and raloxifene.","volume":"25","author":"Piperi","year":"2005","journal-title":"J Obstet Gynaecol"},{"key":"R44-20-20210212","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.maturitas.2004.08.004","article-title":"Effect of raloxifene and hormone therapy on serum markers of brain and whole-body cholesterol metabolism in postmenopausal women.","volume":"50","author":"Vogelvang","year":"2005","journal-title":"Maturitas"},{"key":"R45-20-20210212","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s00404-009-1292-9","article-title":"Randomized, controlled study of the effects of raloxifene on high sensitivity C-reactive protein and serum lipids.","volume":"283","author":"Oztas","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"R46-20-20210212","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1097\/01.AOG.0000137349.79204.b8","article-title":"Multiple Outcomes of Raloxifene Evaluation Investigators. Safety and adverse effects associated with raloxifene: multiple outcomes of raloxifene evaluation.","volume":"104","author":"Grady","year":"2004","journal-title":"Obstet Gynecol"},{"key":"R47-20-20210212","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1007\/s00586-012-2404-y","article-title":"Recommendations for raloxifene use in daily clinical practice in the Swiss setting.","volume":"21","author":"Lippuner","year":"2012","journal-title":"Eur Spine J"},{"key":"R48-20-20210212","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/S0378-5122(99)00090-0","article-title":"Characterization of hot flashes reported by healthy postmenopausal women receiving raloxifene or placebo during osteoporosis prevention trials.","volume":"34","author":"Cohen","year":"2000","journal-title":"Maturitas"},{"key":"R49-20-20210212","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.4088\/JCP.10m06610","article-title":"Raloxifene as an adjunctive treatment for postmenopausal women with schizophrenia: a double-blind, randomized, placebo-controlled trial.","volume":"72","author":"Usall","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R50-20-20210212","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/jama.285.6.785","article-title":"Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy.","volume":"285","year":"2001","journal-title":"JAMA"}],"container-title":["Obstetrical & Gynecological Survey"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/OGX.0b013e31828baef9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T00:33:50Z","timestamp":1620952430000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00006254-201306000-00020"}},"subtitle":["Mechanism of Action, Clinical Efficacy, Adverse Effects, and Contraindications"],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/ogx.0b013e31828baef9","relation":{},"ISSN":["0029-7828"],"issn-type":[{"value":"0029-7828","type":"print"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}